Carisma Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview

Carisma Therapeutics

05/05/2023 19:11

* Carisma Therapeutics Inc  CARM.OQ   CARM.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 8
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
revenue of $3.731 million, according to the estimate from one
analyst, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Carisma
Therapeutics Inc
is for a loss of 89 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Carisma
Therapeutics Inc is $11​, above​ its last closing price
of $5.10. ​​​

This summary was machine generated May 5 at 18:11 GMT.  All
figures in US dollars  unless otherwise stated